var data={"title":"Intravesical Bacillus Calmette-Guerin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Intravesical Bacillus Calmette-Guerin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/769729?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=intravesical-bacillus-calmette-guerin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Intravesical Bacillus Calmette-Guerin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182029\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Biohazard agent:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">BCG (intravesical) contains live, attenuated mycobacteria. Because of the potential risk for Bacillus Calmette Guerin (BCG) transmission, prepare, handle, and dispose of as a biohazard material. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Disseminated infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">BCG dissemination may occur when administered by the intravesical route. Serious infections, including fatal infections, have been reported. BCG may persist in the urinary tract for several months after BCG instillations and delayed manifestations of disseminated BCG infection may develop months or years after BCG therapy. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">BCG infections have been reported in health care workers, primarily from exposures resulting from accidental needle sticks or skin lacerations during the preparation of BCG (intravesical) for administration. Nosocomial infections have been reported in patients receiving parenteral drugs that were prepared in areas where BCG (intravesical) was reconstituted.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182035\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>TheraCys;</li>\n      <li>Tice BCG</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182036\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ImmuCyst;</li>\n      <li>Oncotice</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182040\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Biological Response Modulator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182074\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bladder cancer:</b> Intravesicular:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">TheraCys: Induction: One dose (81 mg or one vial) instilled into bladder (retain for up to 2 hours) once weekly for 6 weeks  beginning at least 14 days after biopsy or transurethral resection, followed by maintenance therapy of 81 mg (one vial) at 3, 6, 12, 18, and 24 months after initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TICE BCG: Induction: One dose (~50 mg or one vial) instilled into the bladder (retain for 2 hours) once weekly for 6 weeks beginning 7 to 14 days after biopsy (may repeat cycle 1 time if tumor remission not achieved), followed by maintenance therapy of ~50 mg (one vial) approximately once a month for at least 6 to 12 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182075\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182076\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182077\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037460\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacterial urinary tract infection: Withhold treatment until complete resolution. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Persistent fever or acute febrile illness consistent with BCG infection: Discontinue treatment.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182085\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intravesical: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tice BCG: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intravesical [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TheraCys: 81 mg (1 ea) [contains monosodium glutamate (sodium glutamate)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182038\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182078\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For intravesicular (bladder instillation) administration only; <b>do not administer IV, SubQ, IM, or intradermally</b>.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Intravesicular: Patients should not drink fluids for 4 hours prior to instillation. Empty or drain bladder. Instill BCG (intravesical) by gravity; retain for as long as possible, up to 2 hours. Patient should lie prone for at least 15 minutes, then rotate positions (lie on right side, left side, abdomen, and back) every 15 minutes to maximize bladder surface exposure (TICE BCG); for TheraCys, patient may be in an upright position after the first 15 minutes. Following bladder instillation, patients should be instructed to void in a seated position in order to avoid the splashing of urine; burning may occur with the first void following therapy. Prior to flushing, disinfect the urine for 15 minutes with an equal amount of household bleach (this should be done for the first 6 hours after therapy). After administration, patients should drink plenty of water in order to flush the bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130889\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).    </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, and preparation in a controlled device or use of ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator); if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and eye/face and respiratory protection for intravesical administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182044\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bladder cancer:</b> Treatment and prophylaxis of carcinoma in situ of the urinary bladder; prophylaxis of primary or recurrent superficial or minimally invasive (stage Ta and/or T1) papillary tumors following transurethral resection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: BCG (intravesical) is not recommended for stage Ta low-grade papillary tumors unless judged to be at high risk for recurrence. BCG (intravesical) is not recommended for immunization against tuberculosis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182031\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">BCG (intravesical) may be confused with BCG vaccine (immunization)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28613961\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Malaise (&le;40%), chills (9% to 34%), pain (&le;17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;16%), vomiting (&le;16%), anorexia (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria (52% to 60%), irritable bladder (50% to 60%), urinary frequency (40% to &le;50%), urinary urgency (6% to &le;50%), hematuria (26% to 39%), cystitis (6% to 30%), urinary tract infection (2% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&le;21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (24% to 33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (17% to 38%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&le;7%), dizziness (&le;2%), headache (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (3%), skin rash (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (&le;6%), abdominal pain (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Genital pain (10%), nephrotoxicity (10%), hemorrhagic cystitis (9%), bladder spasm (&le;8%; including contracted bladder), bladder pain (&le;6%), urinary incontinence (2% to 6%), nocturia (5%), bladder contraction (&le;5%), urine sedimentation abnormality (debris and tissue; &le;2%), epididymitis (&le;1%), orchitis (&le;1%), prostatitis (&le;1%), pyuria (&le;1%), urethritis (&le;1%), urinary tract obstruction (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (&le;5%), blood coagulation disorder (&le;1%); thrombocytopenia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Granulomatous hepatitis (&le;1%), hepatitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (3%; BCG sepsis: &le;1%), abscess (genital; &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthritis (&le;7%), arthralgia (&le;7%), myalgia (&le;7%), muscle cramps (&le;4%), rigors (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary infection (3%), pneumonitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Inflammation (genital; &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Arthritis (reactive), chorioretinitis (granulomatous), conjunctivitis, constipation, erythema nodosum, flank pain, increased blood urea nitrogen, increased serum creatinine, infection (including systemic mycobacterium bovis infection of bone, bone marrow, kidney, lung, liver, lymph nodes, prostate), interstitial pulmonary disease, iritis, keratitis, localized infection (renal abscess), nephritis (includes glomerulonephritis, interstitial nephritis, renal tubulo-interstitial nephritis), pneumonia, pyelonephritis, renal failure, urinary retention (includes bladder tamponade and increased post-void residual urine volume), uveitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182052\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to BCG (intravesical) or any component of the formulations, hypersensitivity after a previous administration of BCG (intravesical) or after a previous administration of a medicinal product containing the same substances;  immunosuppressed patients or persons with congenital or acquired immune deficiencies (eg, HIV infection, leukemia, lymphoma, cancer therapy, immunosuppressive therapy such as corticosteroids); active tuberculosis; concurrent febrile illness, urinary tract infection, or gross hematuria; current symptoms or previous history of a systemic BCG reaction; recent (TheraCys: &lt;14 days; TICE BCG: &lt;7 to 14 days) biopsy, transurethral resection (TUR), or traumatic catheterization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182053\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; BCG reaction: A systemic granulomatous illness occurring following exposure to BCG is referred to as a systemic BCG reaction when any of the following are present without another detectable etiology: Fever &ge;39.5&deg;C for &ge;12 hours or &ge;38.5&deg;C for &ge;48 hours; pneumonitis; hepatitis; organ dysfunction outside of the GU tract with granulomatous inflammation; clinical signs of sepsis. It may be difficult to determine if reaction is due to infection process or inflammatory hypersensitivity. A systemic BCG reaction is more likely to occur with intravesical administration &lt;14 days after a biopsy, transurethral resection (TUR), or traumatic catheterization. Fatalities have been reported with systemic BCG reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bladder irritation: BCG (intravesical) may cause symptoms of bladder irritability which usually begin 4 to 6 hours after instillation and may last 24 to 72 hours; symptoms may increase in severity following each instillation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Disseminated infections: <b>[US Boxed Warning]: May cause disseminated (including fatal) infections following intravesical administration.</b> Instillation to actively bleeding mucosa may promote systemic BCG infection or sepsis. To prevent serious infections, avoid trauma and/or introduction of contaminants into the urinary tract; postpone treatment for at least 1 to 2 weeks (depending on product) following TUR, biopsy, traumatic catheterization (may resume original schedule after 14 days), or gross hematuria. Do not use in patients with concurrent infections. Use caution in patients with aneurysms and prosthetic devices; ectopic BCG infection may occur at these sites. If signs and symptoms of a systemic BCG infection occur, permanently discontinue BCG treatment and begin therapy with 2 or more antimycobacterial agents (do not use single-agent therapy) while conducting a diagnostic evaluation. Infection from BCG (intravesical) is not sensitive to pyrazinamide. Do not use prophylactic antimycobacterial therapy to prevent local adverse events during treatment (there is no data to support use and may alter efficacy). Determine PPD status prior to use (rule out active tuberculosis prior to treatment initiation). Prior to intravesical instillation, patients with a positive PPD test should be further assessed for signs and/or symptoms of active or latent tuberculosis. BCG may persist in the urinary tract for several months after treatment; delayed manifestations of disseminated BCG infection may develop months to years after BCG therapy. Patients who receive immunosuppressive therapy after BCG therapy may be at higher risk for disseminated infection. Monitor for signs/symptoms of infection/toxicity after each treatment. Discontinue for persistent fever or acute febrile illness consistent with BCG infection. Some male genitourinary tract infections (orchitis or epididymitis) have been refractory to multiple antituberculosis drug therapies and have required orchiectomy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Small bladder capacity: Intravesical instillation may be associated with increased risk of severe local reactions in the presence of small bladder capacity; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Urinary tract infection: If a bacterial urinary tract infection occurs during therapy, withhold instillation until complete resolution of infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Biohazard agent: <b>[US Boxed Warning]: Contains live, attenuated mycobacteria. Use appropriate precautions for handling and disposal. BCG is a biohazard; proper preparation technique, handling, and disposal of all equipment in contact with BCG as a biohazard material is recommended.</b> BCG infections have been reported in health care workers due to accidental exposure (needle stick, skin laceration); nosocomial infections have been reported in patients (including immunosuppressed patients) receiving parenteral medications prepared in areas where BCG was prepared. To avoid cross contamination, do not prepare parenteral medications in an area where BCG has been prepared.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: BCG (intravesical) is not a vaccine for the prevention of cancer. Information is not available for interchanging products used for intravesical administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182062\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182059\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=102734&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antibiotics: May diminish the therapeutic effect of BCG (Intravesical).<b> Exceptions: </b>Acetic Acid (Otic); Acetic Acid (Topical); Aluminum Acetate; Azithromycin (Ophthalmic); Aztreonam (Oral Inhalation); Bacitracin (Ophthalmic); Bacitracin (Topical); Chlortetracycline; Ciprofloxacin (Ophthalmic); Clindamycin (Topical); Dapsone (Topical); Dibrompropamidine (Ophthalmic); Dibrompropamidine (Topical); Erythromycin (Ophthalmic); Erythromycin (Topical); Fidaxomicin; Framycetin; Fusidic Acid (Ophthalmic); Fusidic Acid (Topical); Gatifloxacin; Gentamicin (Ophthalmic); Gentamicin (Topical); MetroNIDAZOLE (Topical); Mupirocin; Nitrofurazone; Ozenoxacin; Sulfacetamide (Ophthalmic); Tobramycin (Ophthalmic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hexaminolevulinate: BCG (Intravesical) may diminish the diagnostic effect of Hexaminolevulinate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of BCG (Intravesical).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Myelosuppressive Agents: May diminish the therapeutic effect of BCG (Intravesical).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182047\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182048\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. BCG (intravesical) is not recommended for use in pregnant women. Women of childbearing potential should be advised to avoid pregnancy while on BCG (intravesical) therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182051\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if BCG (intravesical) is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue breast-feeding or avoid use of  BCG (intravesical), taking into account the importance of BCG (intravesical) to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182080\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PPD test prior to treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Intravesical treatment: Monitor for signs/symptoms of toxicity/infection following every treatment. Signs that antituberculous therapy may be needed: Flu-like symptoms &ge;72 hours, fever &ge;101.3&deg;F, systemic symptoms which worsen with each treatment, persistently abnormal liver function tests, prostatitis, epididymitis or orchitis of &gt;2 to 3 day duration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182070\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">BCG (intravesical) is an attenuated strain of bacillus Calmette-Gu&eacute;rin (<i>Mycobacterium bovis</i>) used as a biological response modifier. BCG, when used intravesicularly for treatment of bladder carcinoma <i>in situ</i>, is thought to cause a local, chronic inflammatory response involving macrophage and leukocyte infiltration of the bladder. BCG (intravesical) is active immunotherapy which stimulates the host's immune mechanism to reject the tumor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182087\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (TheraCys Intravesical)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg/vial (1): $204.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Tice BCG Intravesical)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $182.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28182089\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>BCG Cultivo SSI (AR);</li>\n      <li>BCG Inmunoterapia SSI (CL);</li>\n      <li>BCG vaccine (AE, SA);</li>\n      <li>BCG Vaccine (BG);</li>\n      <li>BCG-medac (DE, EE, FR, LT, LV, NO, RO, SI, SK);</li>\n      <li>BCG-Medac (HR, TH);</li>\n      <li>Immucyst (BG, BR, CH, CN, FR, HU, KR, LB, MY, NZ, PT, SG, TH);</li>\n      <li>ImmuCyst (GB);</li>\n      <li>OncoTICE (AT, DE, GB, GR, NL, NO, NZ, PE, PK, PT);</li>\n      <li>Oncotice (AU, ES, FI, IL, KR, LU, MX, TR, VE);</li>\n      <li>OncoTice (SE, VN);</li>\n      <li>Vejicur (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    TheraCys (BCG) [prescribing information]. Swiftwater, PA: Sanofi Pasteur; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TheraCys (BCG) [prescribing information]. Swiftwater, PA: Sanofi Pasteur; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TICE BCG [prescribing information]. Whitehouse Station, NJ: Merck Sharpe &amp; Dohme; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TICE BCG [prescribing information]. Whitehouse Station, NJ: Merck Sharpe &amp; Dohme; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 102734 Version 41.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F28182029\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28182035\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28182036\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28182040\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28182074\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28182075\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28182076\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28182077\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F46037460\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28182085\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F28182038\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28182078\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130889\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28182044\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28182031\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28613961\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28182052\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28182053\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28182062\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28182059\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28182047\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28182048\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28182051\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28182080\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28182070\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28182087\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F28182089\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/102734|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=intravesical-bacillus-calmette-guerin-patient-drug-information\" class=\"drug drug_patient\">Intravesical Bacillus Calmette-Guerin: Patient drug information</a></li></ul></div></div>","javascript":null}